Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Kayla Beaudoin CGS M Application

FY 2024-25

Summary
Inflammatory bowel disease (IBD) is a chronic autoimmune condition affecting the gastrointestinal tract, with Canada reporting the highest rates worldwide. While the cause is unclear, IBD is influenced by genetics, environmental factors, immune responses, and gut microbiota. A high-protein diet (HPD) is a known risk factor for IBD, potentially due to branched-chain amino acids (BCAAs) in protein-rich foods that activate mTOR, a cellular pathway involved in inflammation and immunity, impacting IBD severity. The gut microbiota metabolizes proteins, producing compounds like branched-chain fatty acids (BCFAs), influencing mTOR activation and disease severity. However, how microbial protein metabolism affects IBD remains unclear. I hypothesize that microbial protein metabolism produces bioactive compounds that affect mTOR activation and IBD severity. To test this, mice with varying gut microbiota complexity, each on a control diet (CD) or HPD, will be used to assess protein metabolism and mTOR activation. Human intestinal and myeloid cells will be treated with metabolites of interest to further evaluate their effect on mTOR activation. Colitis will be chemically induced in mice with different gut microbiota complexities, and either a CD or HPD will be used to study the impact of microbial protein metabolism on inflammation and disease progression. These studies will assess metabolite microbial production (amino acids and fats) and disease severity markers such as intestinal permeability, mucosal inflammation and mTOR and autophagy activation. Current IBD treatments often lead to side effects and lose effectiveness over time, highlighting the need for new therapies. This research will inform dietary recommendations, novel therapeutics, and prevention strategies.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530205
Name
Beaudoin Kayla D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Kayla Beaudoin CGS M Application
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Colitis; Gastroenterology; High Protein Diet; Inflammatory Bowel Disease; Intestinal Inflammation; Microbial Protein Metabolism; Microbiome; Mtor; Nutrition
Abstract
Inflammatory bowel disease (IBD) is a chronic autoimmune condition affecting the gastrointestinal tract, with Canada reporting the highest rates worldwide. While the cause is unclear, IBD is influenced by genetics, environmental factors, immune responses, and gut microbiota. A high-protein diet (HPD) is a known risk factor for IBD, potentially due to branched-chain amino acids (BCAAs) in protein-rich foods that activate mTOR, a cellular pathway involved in inflammation and immunity, impacting IBD severity. The gut microbiota metabolizes proteins, producing compounds like branched-chain fatty acids (BCFAs), influencing mTOR activation and disease severity. However, how microbial protein metabolism affects IBD remains unclear. I hypothesize that microbial protein metabolism produces bioactive compounds that affect mTOR activation and IBD severity. To test this, mice with varying gut microbiota complexity, each on a control diet (CD) or HPD, will be used to assess protein metabolism and mTOR activation. Human intestinal and myeloid cells will be treated with metabolites of interest to further evaluate their effect on mTOR activation. Colitis will be chemically induced in mice with different gut microbiota complexities, and either a CD or HPD will be used to study the impact of microbial protein metabolism on inflammation and disease progression. These studies will assess metabolite microbial production (amino acids and fats) and disease severity markers such as intestinal permeability, mucosal inflammation and mTOR and autophagy activation. Current IBD treatments often lead to side effects and lose effectiveness over time, highlighting the need for new therapies. This research will inform dietary recommendations, novel therapeutics, and prevention strategies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beaudoin, Kayla D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~